ATE532524T1 - Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs - Google Patents

Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs

Info

Publication number
ATE532524T1
ATE532524T1 AT02731178T AT02731178T ATE532524T1 AT E532524 T1 ATE532524 T1 AT E532524T1 AT 02731178 T AT02731178 T AT 02731178T AT 02731178 T AT02731178 T AT 02731178T AT E532524 T1 ATE532524 T1 AT E532524T1
Authority
AT
Austria
Prior art keywords
polysaccharide
cancer
treatment
chemotherapeutic agent
simultaneous administration
Prior art date
Application number
AT02731178T
Other languages
German (de)
English (en)
Inventor
Anatole Klyosov
David Platt
Original Assignee
Pro Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/818,596 external-priority patent/US6645946B1/en
Application filed by Pro Pharmaceuticals Inc filed Critical Pro Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE532524T1 publication Critical patent/ATE532524T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT02731178T 2001-03-27 2002-03-27 Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs ATE532524T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/818,596 US6645946B1 (en) 2001-03-27 2001-03-27 Delivery of a therapeutic agent in a formulation for reduced toxicity
US31709201P 2001-09-04 2001-09-04
PCT/US2002/009524 WO2002076474A1 (en) 2001-03-27 2002-03-27 Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE532524T1 true ATE532524T1 (de) 2011-11-15

Family

ID=26980760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731178T ATE532524T1 (de) 2001-03-27 2002-03-27 Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs

Country Status (7)

Country Link
US (1) US7012068B2 (enExample)
EP (1) EP1383516B1 (enExample)
JP (1) JP4744782B2 (enExample)
AT (1) ATE532524T1 (enExample)
DK (1) DK1383516T3 (enExample)
ES (1) ES2376739T3 (enExample)
WO (1) WO2002076474A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005037293A1 (en) * 2003-10-16 2005-04-28 Univ Monash Immunomodulating compositions and uses therefor
KR20060127874A (ko) * 2003-12-12 2006-12-13 타이요 카가꾸 가부시키가이샤 장질환 개선용 조성물
JP2008503583A (ja) * 2004-06-22 2008-02-07 プロ−ファーマシューティカルズ,インコーポレイティド 抗がん薬、抗血管形成薬、及び多糖類を共デリバリーするための組成物及び方法
US20080286251A1 (en) * 2004-08-02 2008-11-20 Propharmaceuticals, Inc. Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
WO2011016811A1 (en) * 2009-08-07 2011-02-10 Pro-Pharmaceuticals, Inc. Methods for reducing the incidence of chemotherapy - induced mucositis
US8604187B2 (en) * 2010-01-14 2013-12-10 North Texas Medical Associates Compositions and methods of aloe polysaccharides
ES2698101T3 (es) 2012-10-10 2019-01-31 Galectin Therapeutics Inc Compuestos de carbohidrato con restos de galactosa para el tratamiento de la nefropatía diabética y trastornos asociados
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
CA3102155A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US5118673A (en) * 1982-05-07 1992-06-02 Carrington Laboratories, Inc. Uses of aloe products
WO1993008810A1 (en) * 1991-11-05 1993-05-13 Carrington Laboratories, Inc. Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure
JP3801658B2 (ja) 1993-03-02 2006-07-26 太陽化学株式会社 β−グルクロニダーゼ活性抑制組成物
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
WO1996004014A1 (en) 1994-07-29 1996-02-15 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Controlled-release drug preparation
US5861142A (en) * 1996-03-25 1999-01-19 Schick; Mary Pichler Method for promoting hair, nail, and skin keratinization
WO1998050018A1 (en) * 1997-05-06 1998-11-12 Xiao Yu Wu Drug delivery system
NZ507211A (en) 1998-03-26 2003-07-25 Fujisawa Pharmaceutical Co Sustained release preparations
KR20000011247A (ko) * 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
ID28275A (id) 1998-09-28 2001-05-10 Warner Lambert Co Penghantaran kolon dan enterik yang menggunakan kapsul-kapsul hpmc
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT

Also Published As

Publication number Publication date
DK1383516T3 (da) 2012-02-20
EP1383516A4 (en) 2007-08-01
US7012068B2 (en) 2006-03-14
JP4744782B2 (ja) 2011-08-10
EP1383516B1 (en) 2011-11-09
JP2004525143A (ja) 2004-08-19
US20030064957A1 (en) 2003-04-03
ES2376739T3 (es) 2012-03-16
WO2002076474A1 (en) 2002-10-03
EP1383516A1 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
ATE532524T1 (de) Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
ATE328599T1 (de) Antitumorale mittel
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
PT1420801E (pt) Utilização de fucanos no tratamento de adesões, artrite e psoríase
GEP20063805B (en) Alkyne-Arylnaphthyridin-4-one as Phosphodiesterase-4 Inhibitors
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
NO20054988D0 (no) Preparater og metoder for behandling av cancer
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
PL373302A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
ATE441423T1 (de) Verwendung von mastix und dessen ätherischen ílen zur verhinderung oder bekämpfung von mikrobieller infektionen
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
DE60036915D1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
WO2005025501A3 (en) Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
FR2846327B1 (fr) Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
PL368686A1 (en) Novel aminobenzoephenones
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
MXPA05013827A (es) Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer